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bzxiang@hkbu.edAbstract Developing new pharmaceuticals requires massive amounts of time, money and efforts. The
key step is how to ﬁnd a safe and effective entity for a disease condition and how to develop it as new
drug effectively. Unfortunately, the FDA’s rate of approving new entities has declined dramatically in
the last three decades. There is a strong need to review the current strategy and to optimize process in
developing new drugs, both to shorten the process and increase the success rate. Chinese medicine has
used natural products to treat patients for thousands of years, and Chinese medicine practitioners have
chronicled the patients and treatment methods for thousands of years. There is much information that
has not yet been used. The success stories of artimisinin and arsentic trioxide are wonderful examples of
how the annals of Chinese medicine can provide leads for discovering new drugs. This paper argues
that the annals of Chinese medicine are valuable and describes how they can be used in modern drug
discovery. The major topics addressed are: (i) why Chinese medicine is a rich resource for ﬁnding new
drugs; (ii) how to identify a potential valuable record from Chinese medicine annals; (iii) when a
potential valuable record is identiﬁed from annals, how to proceed; and (iv) both why and how the
approach used for chemical drugs should be revised for drugs based on the historical documents related
to herbal medicine. In conclusion, we argue here that the annals of Chinese medicine offer not only a
rich resource for new drugs, but also several centuries of patient data with regard to safety and efﬁcacy,
that in effect represent pilot studies. Acknowledging and using these data can shorten new drug
discovery time and improve efﬁciency of the drug development process, bringing more effective, safe
drugs to market much more quickly and cheaply.
& 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.edica, Chinese Academy of Medi
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Zhaoxiang Bian et al.21. Introduction
New drug development as currently practiced in the West is
a long-term, incredibly expensive and very inefﬁcient process.
In the last three decades, life science researches have provided
reasonable sound prognosis for a number of therapeutic
targets for which more and more new molecular entities could
be designed/or puriﬁed for new drug development. Yet,
marketing approval by the US Food and Drug Administration
(FDA), through strict preclinical study to clinical trials, has
declined dramatically since 19871. For example, only 20 new
drugs were approved by the US FDA in the 2005 ﬁscal year,
compared with 36 in 2004 and 53 in 19962. Currently, the
development process for a new drug typically takes between 10
and 15 years, and this process is associated with a ﬁnancial
investment of hundreds of thousands to over one billion US
dollars3. Many factors may contribute to the length and low
success rate of new entities’ identiﬁcation, such as lack of
predictive preclinical models, unpredicted severe toxicity,
inappropriate pharmacokinetics, etc. Most importantly,
because of the difference between human subjects and test
animals, some drugs under investigation failed in clinical
testing as these entities do not behave pharmacologically as
they did in animal studies. This big gap between human and
animal models has caused a big barrier to translate the
promising entity in animal models to human being in the
clinic. Therefore, there is a strong need for new strategy(s) to
optimize current new drug development process, both to
shorten the process and increase the success rate.
Chinese medicine has been in use for thousands of years.
The practitioners of Chinese medicine have been recording
their experiences for an equally long period of time. The
annals of Chinese medicine comprise literally thousands of
case histories and formulas for different conditions. These case
records could be treated as a pilot study in the new drug
development thus to improve the success rate and shorten the
process of new drug development.2. Why are the annals of Chinese medicine a reliable resource?
Chinese medicine originates from natural products. It is well
known that natural products dominated new drug development
in the 20th century up until the 1990s. The ﬁrst isolation of
pharmacologically active pure compound morphine from opium
produced by cut seed pods of the poppy, Papaver somniferum,
around two hundred years ago4, initiated an era to develop new
drugs through massive screening from natural substances. By
1990, around 80% of drugs were either natural products or their
analogs. In the 1990s, however, synthetic medicinal chemistry
virtually took over, and the proportion of nature product-based
new drugs dropped to 50% of all FDA-approved new drugs. In
the past 15 years many pharmaceutical ﬁrms have eliminated
natural product research. Thus, this decline seems to predict an
end of an era with natural products as a source for new entities
identiﬁcation for new drug development. Different opinions
exists1. But many experts believe that untapped biological
resources, ‘smart screening’ methods, robotic separation with
structural analysis, metabolic engineering, and synthetic biology
offer exciting technologies for new natural product drug
discovery. And those advances in rapid genetic sequencing,
coupled with manipulation of biosynthetic pathways, mayprovide a vast resource for the future discovery of pharmaceu-
tical agents1.
Chinese medicine, as many other traditional medicines such
as Ayurveda medicine, Indian medicine and European medi-
cine, has used natural products to treat patients for thousands
of years. Most importantly, Chinese medicine is still being
applied in the current clinical practice after the conventional
medicines have been developed for around two hundred years.
Furthermore, Chinese medicine doctors have accumulated
huge volume of written records. Since time immemorial,
Chinese people have used natural products, such as plants,
minerals, and animals, around to treat disease, and these
activities were chronicled. As said in the Chinese medicine
literature ‘SanNon tested one hundred plants, and experienced
toxicity seventy times in one day’5. Experience and practice,
accumulated from hundreds of doctors over centuries, are the
foundation of the Chinese pharmacopoeia and of modern
Chinese medical practice. The many references of Chinese
medicine list the actions of each Chinese materia medica
(CMM) and include many case studies, demonstrating the
effectiveness of these CMMs in the form of single components
or as ingredients in mixtures. These annals, as a result from
accumulated treatment experience in human being, should be
treasured, and a new entity search from natural products
could be beneﬁted from this approach.
Actually, the annals of Chinese medicine have already
played an important role in guiding new drug development.
The discovery of arsenic trioxide for treating acute promye-
locytic leukemia (APL) is a typically successful example6.
Pishuang (arsenic trioxide) has been used therapeutically for
a long time for the treatment of a variety of diseases in
China. Detailed explanations about its function are recorded
in ‘Shennong’s Classic of Materia Medica’, compiled in the
Han dynasty5. Han TY from Harbin Medical University
found in anecdotes that one Chinese medicine formula with
Pishuang, mercurous chloride (Qingfen) and Veneum bufonis
(Chanchu) can treat lymphatic tuberculosis and carcinoma in
19716. Han TY designed and administered the formula as an
intramuscular injection, and some cancer patients beneﬁted
from this treatment, but unfortunately, the side effects were
so serious that the practice was abandoned. In 1972, Dr
Zhang TD paid attention to this anecdote again, studied the
side effects from the formulation, and ﬁnally concluded that
the side effects were primarily caused by mercurous chloride
and veneum bufonis. Zhang TD and his colleagues success-
fully modiﬁed the formula, reduced its toxicity while con-
served its beneﬁts. They then conducted clinical trials to test
the efﬁcacy of arsenic trioxide against leucocythemia from
1973 to 1992. During this period, 12 clinical reports with
arsenic trioxide for leukemia were published in medical
journals in China7,8. In these reports, the efﬁcacy of arsenic
trioxide in treating acute leucocythemia was demonstrated,
although there were no control groups in most of the studies.
His research ﬁnally attracted great attention from China and
worldwide, and Science published a news item titled, ‘Ancient
remedy performs new tricks’, reporting Zhang TD and his
colleagues’ breakthrough in 19969. Cell Therapeutics, a drug
company in USA, developed it as a new drug, taking it
through strict preclinical and clinical stages. Finally, arsenic
trioxide was approved as a new drug named Trisenox by the
US FDA in September 2000 to treat patients with a severe
form of leukemia whose disease have recurred or who have
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process for Trisenox was rapid, and the drug was approved
for marketing only three years after the clinical study was
ﬁrst started in the USA. Currently, arsenic trioxide, alone or
in combination with other substances, is a ﬁrst-line therapy
in newly diagnosed acute promyelocytic leukemia with high
rates of complete remission and molecular remission10. This
case illustrates how new drug development originating from
the annals of Chinese medicine can be far more efﬁcient,
taking far less time and resources. It also demonstrates the
diligence of Chinese doctors in both recording their experi-
ences accurately and precisely, and in reading what their
predecessors and colleagues have done. Such accurate
recording is part of the heritage of the practice of Chinese
medicine since time immemorial. This breakthrough would
not have happened if Han TY had not founded the anecdote,
both positive and negative; nor would it have happened if
Zhang TD and his team had not paid attention to both of
these records. Equally important, the drug would have
reached pharmacy shelves if clinical trials had not been
conducted. This example clearly shows how the experiences
of Chinese doctors as recorded in the annals of Chinese
medicine can be used to improve drug discovery and devel-
opment in modern pharmacognosy.3. How to identify a potentially valuable record from Chinese
medicine annals?
The annals of Chinese medicine, the written records by
Chinese medicine practitioners from different dynasties of
China, can be a useful resource for drug development. Those
records are all written in Chinese, but all – even those written
3000 years ago – can be read and understood by modern
Chinese readers. The major content of these annals include the
basic theories of Chinese medicine, clinical usage strategies
and the application of Chinese medicine. Most importantly,
most of case reports about the treatment are involved in
annals. The volume of records about the usage of CMM in the
classic literatures is huge, and, until recently, entirely in
Chinese. How can a researcher, especially non-Chinese read-
ing researcher, identify a CMM that is potentially valuable for
new drug development? The following steps provide an
effective strategic approach.
For a non-Chinese reading researcher, ﬁrstly to ﬁnd a
collaborator who is familiar with Chinese is important.
Although those classic annals are written in Chinese, language
is an obstacle but not a barrier.
Secondly, after identifying a disease as a target, the
important step is to determine what terms you are looking
for in the Chinese literatures. The common difﬁculty here is
the difference between modern Western descriptions of a
condition and ancient Chinese records. Differences both in
language and concept make it difﬁcult to match the targeted
disease with that in the classic literature—even though we can
assume that people in ancient times suffered from exactly the
same conditions today. One, and possibly the best, approach is
to focus on the major symptom(s) of disease. Clinical
symptoms are the same for a disease, both for different
cultures and for different time periods.
Here is one example of how we searched for herbs that
might provide drugs to treat irritable bowel syndrome (IBS).IBS is a modern term, created in 1950, used to describe a
speciﬁc set of gastrointestinal symptoms11. While the term
‘‘irritable bowel’’ does not appear in classic Chinese litera-
tures, the symptoms – abdominal pain and a change in bowel
habit – do appear. Searching the Chinese material for these
symptoms produced a number of references and formulas. Of
these, the one that seemed most relevant to IBS is a formula-
tion named ‘Important Formula for Painful Diarrhea’ from
Collected Treatises of Zhang JY. This formula, originally
known as Atractylodes Macrocephala and Peony Powder
(Bai Zhu Shao Yao San), is attributed by Zhang JB to Liu
CC of the Yuan Dynasty. It is also mentioned in an unnamed,
15th-century text by Zhu ZH, as treatment for painful
diarrhea, which are the main characteristics of diarrhea-
predominant IBS12. In modern TCM clinics this formula has
been used for IBS treatment for decades. A recent systematic
review has shown that this formula is effective for treating
IBS13. It has potential as a new remedy for IBS, and also as a
source of chemical compound-based new drug(s). Thus,
searching the CMM records for symptoms of modern com-
plaints as deﬁned in Western terms is an effective and
productive strategy for ﬁnding new drugs.
The third step is to collect all related records for a speciﬁc
condition. For the records in the classic literature, the ideal
way is to collect all related records from the ancient references,
but it is not as easy as might be expected. The classic Chinese
medicine literature database, ‘Encyclopedia of traditional
Chinese medicine’ provides a good platform for beginning to
search14. It is an electronic database with information col-
lected from major Chinese medicine reference books published
before 1949 and around 10,000 Chinese medicine medical
literature books were collected. For records after 1949, two
databases can be searched, namely Chinese Journal Net, which
represents most medical references published since 1911, and
the CQVIP database, which represents medical references
published since 200215. The ‘Encyclopedia of traditional
Chinese medicine’ (about the classic literature) and the two
current databases are in Chinese only, with no English
translation. As mentioned before, a non-Chinese reading
researcher would overcome this difﬁculty through collabora-
tion with a Chinese reader.
The forth step is to systematically review collected records
to identify those worth further study. For controlled study,
systematic review and meta-analysis are powerful tools for
analyzing records16. Unfortunately, for the classic Chinese
literatures, no established well-recognized method to system-
atically assess those records exists now. Nevertheless, even
though controlled studies are rare in the annals of Chinese
medicine, some information about the efﬁcacy and safety of a
treatment remedy for a speciﬁc syndrome or a condition can
be found. This information may include the formula, dosage,
preparation method, treatment course, indication and special
precaution. Systematically assessing these data is a crucial step
for distilling valuable information from the annals. Normally,
repeated records with one herb or a formula for one condition
provide stronger evidence than a single record. Furthermore,
in line with the classic annals, recent case records or clinical
trials supporting efﬁcacy claims may be more valuable than
ancient records. For example, the anecdotes of arsenic trioxide
did appear in ancient times, but also appeared in the 1970s7,8;
they simply did not get much attention until Zhang TD and
his team recognized their relevance in the 1990s.
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medicine to ﬁnd a lead on a potentially valuable new drug,
the ﬁrst step is to ﬁnd a collaborator who is a Chinese
reader for a non-Chinese reading researchers, and secondly
to identify symptoms in Chinese medical terms. Searching the
annals’ databases for those terms will generate case reports as
the third step. The forth step is to scrutinize the data. These
steps can lead to ﬁnding relevant and valuable leads toward
new drugs.4. When a potential valuable record is identiﬁed from annals,
what should be the next step toward new drug development?
Identifying a potentially valuable record from the annals is
only a ﬁrst step toward new drug discovery. The next steps are
to assess its efﬁcacy, safety and reliability.
In the classic annals, for evaluating the efﬁcacy and safety
of herb(s) and formulas, records always rely on comparing
patients’ symptoms pre- and post-treatment with herbs or
formula, but rarely compare patients receiving and not
receiving the treatment. The potential risk in basing conclu-
sions on pre- and post-treatment comparison is that the
difference(s) may come from the natural course of a disease
rather than the effects of intervention. That is the reason why
controlled study between different subjects with or without
intervention are done and considered more reliable. It is
known that case records with pre- and post-comparison
dominate the classic annals of Chinese medicine. One rare
example is a record in the Atlas of Materia Medica (Ben Cao
Tu Jing) originally published in 106117. This anecdote records
a test of the efﬁcacy of ginseng on different persons in a
running competition. The results showed that the participant
who did not consume ginseng was short of breath sooner than
his counterpart who had taken ginseng. Although the aspect
of comparison existed, the case was only a rare exception to
the main stream annals in which efﬁcacy and safety was
assessed based on the difference between pre- and post-
treatment in the same patients rather than comparing changes
in patients of treatment and controlled groups. It is difﬁcult to
generalize the results from such setting of comparison. There-
upon, if a potential valuable record is identiﬁed from classic
annals, it is necessary to test its reliability, and the best way is
to conduct a small-scale randomized controlled trial.
How to test the reliability of potential valuable record from
classic annals is a critical issue for new drug development.
Through animal model study or clinical trial are arguable. On
one hand, animal experiments have contributed much to new
drug development, especially for the effectiveness screening
and the understanding of mechanism of drug efﬁcacy. On the
other hand, the value of animal study in predicting the
effectiveness of intervention in the human subjects has
remained controversial18. Thus, clinical trials are considered
essential because animal study cannot provide sufﬁcient
certainty what will happen in human patients. For the
identiﬁed potential valuable records from annals, testing it
on human subjects in a well designed trial is more direct than
to test it ﬁrst in an animal model. Because the intervention has
already been used on humans, generally over centuries, as
recorded in the annals, this approach is reasonable to save
time and effort. One point should be mentioned: while testing
potentially new drugs directly on humans seems to bereasonable, due to the history of their use in the annals, but
in the trials, it is necessary to pay particular attention to the
drug delivery approach- that is, the form and the dosage of the
intervention, as used in the annals. In a validation trial, any
change to these factors should be considered carefully; if the
changes are reasonable, they should not change the safety of
the intervention.
As for records from current literatures, especially from
reports of clinical trials, the design, implementation, and the
reporting quality are the key factors that determine the
reliability of these records. Reviews of the quality of rando-
mized controlled trials with Chinese medicine show that
quality is a big problem, which should be improved signiﬁ-
cantly19,20. If those trials evaluating efﬁcacy and safety of
Chinese medicine were of high quality, there would be no need
to repeat these trials if there is a potential to develop it as a
new drug. In the case of the discovery of arsenic trioxide,
clinical trial played a very important role to conﬁrm the
reliability of the classic annals; in particular, a trial published
in the journal Blood (1999)8, indicating that the signiﬁcant
effect of arsenic trioxide for remission was induction for APL,
and describing its underlying mechanism, did much to conﬁrm
the efﬁcacy of artemsinin. This trial put the traditional remedy
squarely in the mainstream of chemotherapy research, and
thus sparked new drug development. Unfortunately, however,
because of low quality of clinical trial of CMM, certainty
conclusions about safety and efﬁcacy cannot be made from
these studies19,20. Therefore the quality of such trials should be
improved signiﬁcantly. In addition, the reporting quality of
trials with Chinese medicine should be improved extensively as
well. The dissemination of Consolidated Standards of Report-
ing Trials (CONSORT) Statement has not only improved the
quality of study reporting, but also improved the quality of
study design and implementation21. Recently, its elaboration
for traditional Chinese medicine (CONSORT for TCM) has
been drafted by introducing the speciﬁcities of TCM22.
We recommended that all clinical studies should be imple-
mented rigorously and be reported concisely on the basis of
CONSORT for TCM Statements.
In addition, the ongoing or completed study protocol
should also be registered, although trial registration alone
may not appear to reduce a bias toward results and conclu-
sions favoring new drugs23, it can improve the transparency of
clinical trials and minimize publication bias. Moreover, these
databases can also be a platform for peers to share their
research approaches, promoting collaboration and inspiring
new ideas.
Evaluating the reliability of a potentially valuable record
form the annals is necessary for new drug development. A
well-designed high quality clinical trial is a crucial step in this
evaluation.5. Traditional approach should be revised for new drug
development based on annals of Chinese medicine
In conventional medicine, new drug development commences
with determining the mechanism of disease, followed by the
design and synthesis of therapeutically active compounds or
molecules that target that mechanism, or by the identiﬁcation
of active compound from natural products. When a potential
entity is synthesized or puriﬁed, as shown in Fig. 1, it typically
Figure 1 Schematic representation of new drugs development with typical time frames form new drug discovery (new entity) from FDA
and SFDA (Cited from text Book ‘‘Metabolism, Pharmacokinetics and Toxicity of Functional Groups: Impact of Chemical Building
Blocks on ADMET’’).
Figure 2 Schematic representation of new drugs development with
based on compound identiﬁcation from annals of Chinese medicine.
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and then in vivo in laboratory animals to evaluate toxic and
pharmacological effects24. Then four phases (phase I to IV) of
clinical trials in humans follow. In phase I, pharmacokinetics,
safety, gross effects are studied on human volunteers. If the
drug passes the test, phase II will be conducted, where
pharmacokinetics, safety, therapeutic efﬁciency are studied
on selected patients. If the drug passes the phase II study,
additional safety and therapeutic effectiveness are further
investigated in phase III. If the drug passes the strict trials
of Phase III, the drug will be approved and marketed. Phase
IV comprises post-marketing surveillance with regard to
adverse drug reaction(s) and efﬁcacy24. Although the whole
process is comprehensive, it is a high-risk proposition that has
shown, historically, a failure rate of more than 90%24.
Therefore, pre-phase I (phase 0) study is a designation for
exploratory, ﬁrst-in-human trials to accelerate the discovery
and development of new molecular entitles proposed in 2006
Guidance on Exploratory Investigational New Drug (IND)
Studies published by the US FDA25. It allows the demonstra-
tion of drug-target effects and assessment of pharmacokinetic–
pharmacodynamic relationships in humans earlier in clinical
development, although there are opposing opinions on
whether testing a small dose of a novel drug can provide
meaningful information. But when a valuable intervention
identiﬁed from annals of Chinese medicine, the approach for
new drug discovery may need modiﬁcation to some extent,
thus to save time and increase the success rate.
If the identiﬁed entity is the same as that in the annals, and
the component and structure of entity is clear, such as the case
of arsenic trioxide, the revised steps based on traditional
approaches could be: (1) To start from the phase II trial; (2)
and to be followed by long-term animal testing for efﬁcacy and
safety, as listed in Fig. 2. Preclinical testing, short term animal
testing and Phase I trial could be skipped because the historical
human study has already demonstrated efﬁcacy and safety.
If the identiﬁed entity is a complex of different known and/
or unknown compounds, the aim of drug development is to
develop a chemical based new drug, it is necessary to undergo
puriﬁcation, chemical compound identiﬁcation and activity
assessment. In this scenario, the traditional process cannot be
skipped but potential value herb(s) or formulas identiﬁcation
from annals can save time for new compound discovery. The
full approach is listed in Fig. 3. The discovery of artemisinin is
a typical case for this approach26. As mentioned by Prof. TuYY, more than 2000 Chinese herb preparations were investi-
gated and more 640 hits that had possible antimalarial
activities were identiﬁed. Subsequently, more than 380 extracts
obtained from 200 Chinese herbs were evaluated against a
mouse model of malaria. Unfortunately the progress was not
smooth until their team ﬁnally found a way to extract
Artemisia annua L. (Qinghao) with a lower-temperature pro-
cedure based on the inspiration by the extraction method from
a reference relevant to use of Artemisia annua L. for alleviating
malaria symptoms in the Handbook of Prescriptions for
Emergencies (Zhou Hou Bei Ji Fang) written by Ge Hong in
the Jin dynasty. After further work, they obtained a non-toxic,
neutral extract that was 100% effective against parasitemia in
mice infected with Plasmodium bergher and in monkeys
infected with Plasmodium cynomolgi, the causative agents of
malaria. Prof. Tu YY and her colleagues bravely took the risk
of being the ﬁrst human subjects to test the extract from
qinghao; then the ﬁrst clinical trial started in patients infected
with both Plasmodium vivax and Plasmodium falciparum.
Subsequently, Tu and her colleagues moved on to isolate and
purify the active components from Artemisia. Finally, they
Figure 3 Schematic representation of new drugs development with based on new compound identiﬁcation from annals of Chinese
medicine.
Figure 4 Schematic representation of new drugs development
with aim of formula based new therapeutic entity.
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tive, named dihydroartemisinin in 1972, and developed it into a
new chemical drug. Currently, artemisinin is recommended by
the World Health Organization for malaria, and an artemisi-
nin-based combination treatment (ACT) for malaria world-
wide, coartems (artemether 20 mg/lumefantrine 120 mg), was
approved by the US FDA in April 200927. For this elegant,
innovative and important work, Prof. Tu YY won the 2011
Lasker Award for Clinical Medical Research. This research
work is very important not only because it demonstrates the
value of the classic annals of Chinese medicine, but also
because it demonstrates the value of creative interpretation
and adaptation of the knowledge there.
If the identiﬁed entity is an herb or a formula, and the
researchers aim to develop a new drug based on it, such as
Danshen dripping pill, the starting step could be phase II trial and
long term animal testing, as listed in Fig. 4. In this situation, the
preclinical testing and short term animal testing could be skipped
too. Currently, a formulation-based new therapeutic entity is very
common in mainland China. It complies with the Chinesemedicine theories. It is possible that a formula-based new
therapeutic entity be accepted by the world when (1) the clinical
trial can demonstrate the efﬁcacy and safety; (2) quality of Chinese
medicine could be well controlled; and (3) the mechanism of
Chinese medicine could be understand, even partially.6. Conclusions
Traditional Chinese medicine is a treasure. It has played, and
is playing, an important role in curing disease and enhancing
health. Evidence from strict clinical trials is the key to
developing new drug from the annals of Chinese medicine.
The identiﬁcation of a potentially valuable record, the assess-
ment of the reliability of records through clinical trial, and the
revised traditional new drug development approach can
effectively shorten the new drug development process, saving
time and money while bringing effective new drugs to market
efﬁciently—ultimately beneﬁting patients around the world.References
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